Bavarian Nordic A/S announced the award of a contract valued at EUR 65 million to supply its MVA-BN smallpox vaccine to the strategic reserve within the European Union (EU) in 2025. This third, and larger order follows two previous orders, received in 2023 and delivered in 2024, for smallpox vaccines to rescEU stockpiles across Europe and will help to expand the EU?s capability to respond to future biological threats and emergencies by enabling rapid deployment of medical countermeasures to its member states.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
182.8 DKK | +17.14% | +15.55% | +3.01% |
07:21pm | Congo authorities approve mpox vaccines to try to contain outbreak | RE |
11:58am | Bavarian Nordic Files EU Application for Chikungunya Vaccine Candidate | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+3.01% | 1.74B | |
+54.61% | 815B | |
+44.25% | 654B | |
-6.33% | 354B | |
+20.62% | 337B | |
+10.44% | 302B | |
+18.45% | 247B | |
+2.09% | 229B | |
+13.03% | 219B | |
+8.61% | 171B |
- Stock Market
- Equities
- BAVA Stock
- News Bavarian Nordic A/S
- Bavarian Nordic A/S Receives EUR 65 Million Contract to Supply Smallpox Vaccines for EU Strategic Reserve